Wegovy 25mg Tablets contain semaglutide, a GLP-1 receptor agonist used as part of a comprehensive weight management programme in eligible adults.
The oral Wegovy tablet provides a once-daily alternative to injectable Wegovy, containing the same active ingredient, semaglutide. The 25mg tablet is the highest strength in the current Wegovy tablet range, alongside 1.5mg, 4mg and 9mg strengths.
In the UK, Wegovy tablets are authorised for use alongside a reduced-calorie diet and increased physical activity for weight management in eligible adults. Treatment suitability and dose progression should be determined by an appropriately qualified prescriber.
Each pack contains 30 tablets, providing a convenient one-month supply when taken once daily as prescribed.Each Wegovy tablet contains 25mg of semaglutide, the active ingredient responsible for the medicine’s GLP-1 receptor agonist activity.
Wegovy tablets provide an oral formulation of semaglutide, offering an alternative to injectable Wegovy for eligible patients.
Wegovy tablets are taken once daily, according to the prescribed treatment schedule and product instructions.
25mg is the highest strength in the current Wegovy tablet range, following the 1.5mg, 4mg and 9mg strengths.
Each pack contains 30 tablets, corresponding to approximately one month’s treatment when taken once daily.
Wegovy is a prescription-only medicine and should only be supplied following an appropriate clinical assessment and prescription.
Wegovy tablets provide a new oral formulation of semaglutide for eligible patients requiring medical support with weight management.
The 25mg strength forms the highest step in the authorised tablet dose range and may be prescribed following appropriate dose escalation and clinical assessment. The UK dosing schedule starts at 1.5mg and progresses through 4mg, 9mg and 25mg, with a minimum of one month at each dose level.
Key features include:
Wegovy 25mg Tablets are authorised for use as part of weight management in eligible adults, alongside:
Wegovy contains semaglutide, which is a GLP-1 receptor agonist.
Semaglutide acts on GLP-1 receptors involved in the regulation of appetite and food intake. Through its effects on these pathways, Wegovy can support reduced calorie intake as part of a comprehensive weight management programme.
Wegovy should be used alongside a reduced-calorie diet and increased physical activity, as directed by the prescribing clinician.
